Table 2. Clinical parameters of 530 ccRCC patients.
| Clinical parameters | Total | Training group | Testing gruop |
| (n=530) | (n=266) | (n=264) | |
| Age(year, mean±SD) | 60.56±12.14 | 60.52±12.24 | 60.61±12.06 |
| Gender(n,%) | |||
| Male | 344(64.9) | 175(65.7) | 169(64.0) |
| Female | 186(35.1) | 91(34.3) | 95(36.0) |
| Tumor grade(n,%) | |||
| G1 | 14(2.6) | 5(1.9) | 9(3.4) |
| G2 | 227(42.8) | 106(39.8) | 121(45.8) |
| G3 | 206(38.9) | 114(42.9) | 92(34.8) |
| G4 | 75(14.2) | 36(13.5) | 39(14.8) |
| Gx | 5(1.0) | 3(1.1) | 2(0.8) |
| Unknown | 3(0.5) | 2(0.8) | 1(0.4) |
| Pathological stage(n,%) | |||
| Stage I | 265(50.0) | 132(49.6) | 133(50.4) |
| Stage II | 57(10.8) | 33(12.4) | 24(9.1) |
| Stage III | 123(23.2) | 62(23.3) | 61(23.1) |
| Stage IV | 82(15.5) | 37(13.9) | 45(17.0) |
| Unknown | 3(0.5) | 2(0.8) | 1(0.4) |
| AJCC T(n,%) | |||
| T1 | 271(51.1) | 136(51.1) | 135(51.1) |
| T2 | 69(13.0) | 36(13.6) | 33(12.5) |
| T3 | 179(33.8) | 87(32.7) | 92(34.9) |
| T4 | 11(2.1) | 7(2.6) | 4(1.5) |
| AJCC N(n,%) | |||
| N0 | 239(45.1) | 123(46.2) | 116(43.9) |
| N1 | 16(3.0) | 9(3.4) | 7(2.7) |
| Nx | 275(51.9) | 134(50.4) | 141(53.4) |
| AJCC M(n,%) | |||
| M0 | 420(79.2) | 215(80.8) | 205(77.7) |
| M1 | 78(14.7) | 36(13.5) | 42(15.9) |
| Mx | 30(5.7) | 13(4.9) | 17(6.4) |
| Unknown | 2(0.4) | 2(0.8) | - |
| Survival status(n,%) | |||
| Alive | 364(68.7) | 182(68.4) | 182(68.9) |
| Dead | 166(31.3) | 84(31.6) | 82(31.1) |
| Survival months(mean±SD) | 37.88±27.20 | 36.59±26.73 | 39.19±27.64 |
| Risk scores(mean±SD) | 1.31±1.32 | 1.29±1.15 | 1.33±1.46 |
| High(n,%) | 267(50.4) | 133(50.0) | 134(50.8) |
| Low(n,%) | 263(49.6) | 133(50.0) | 130(49.2) |
ccRCC: clear cell renal cell carcinoma; SD: Standard Deviation; AJCC: American Joint Committee on Cancer.